Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer

Abstract A subset of breast cancer patients benefits from preoperative bevacizumab and chemotherapy, but validated predictive biomarkers are lacking. Here, we aimed to evaluate tissue-based angiogenesis markers for potential predictive value regarding response to neoadjuvant bevacizumab treatment in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kristi Krüger, Laxmi Silwal-Pandit, Elisabeth Wik, Oddbjørn Straume, Ingunn M. Stefansson, Elin Borgen, Øystein Garred, Bjørn Naume, Olav Engebraaten, Lars A. Akslen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c8a2b3892eea4e2a921d64ce837fe2d4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c8a2b3892eea4e2a921d64ce837fe2d4
record_format	dspace
spelling	oai:doaj.org-article:c8a2b3892eea4e2a921d64ce837fe2d42021-12-02T12:14:56ZBaseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer10.1038/s41598-021-81914-02045-2322https://doaj.org/article/c8a2b3892eea4e2a921d64ce837fe2d42021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-81914-0https://doaj.org/toc/2045-2322Abstract A subset of breast cancer patients benefits from preoperative bevacizumab and chemotherapy, but validated predictive biomarkers are lacking. Here, we aimed to evaluate tissue-based angiogenesis markers for potential predictive value regarding response to neoadjuvant bevacizumab treatment in breast cancer. In this randomized 1:1 phase II clinical trial, 132 patients with large or locally advanced HER2-negative tumors received chemotherapy ± bevacizumab. Dual Factor VIII/Ki-67 immunohistochemical staining was performed on core needle biopsies at baseline and week 12. Microvessel density (MVD), proliferative microvessel density (pMVD; Factor VIII/Ki-67 co-expression), glomeruloid microvascular proliferation (GMP), and a gene expression angiogenesis signature score, were studied in relation to pathologic complete response (pCR), clinico-pathologic features and intrinsic molecular subtype. We found that high baseline MVD (by median) significantly predicted pCR in the bevacizumab-arm (odds ratio 4.9, P = 0.012). High pMVD, presence of GMP, and the angiogenesis signature score did not predict pCR, but were associated with basal-like (P ≤ 0.009) and triple negative phenotypes (P ≤ 0.041). pMVD and GMP did also associate with high-grade tumors (P ≤ 0.048). To conclude, high baseline MVD significantly predicted response to bevacizumab treatment. In contrast, pMVD, GMP, and the angiogenesis signature score, did not predict response, but associated with aggressive tumor features, including basal-like and triple-negative phenotypes.Kristi KrügerLaxmi Silwal-PanditElisabeth WikOddbjørn StraumeIngunn M. StefanssonElin BorgenØystein GarredBjørn NaumeOlav EngebraatenLars A. AkslenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kristi Krüger Laxmi Silwal-Pandit Elisabeth Wik Oddbjørn Straume Ingunn M. Stefansson Elin Borgen Øystein Garred Bjørn Naume Olav Engebraaten Lars A. Akslen Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
description	Abstract A subset of breast cancer patients benefits from preoperative bevacizumab and chemotherapy, but validated predictive biomarkers are lacking. Here, we aimed to evaluate tissue-based angiogenesis markers for potential predictive value regarding response to neoadjuvant bevacizumab treatment in breast cancer. In this randomized 1:1 phase II clinical trial, 132 patients with large or locally advanced HER2-negative tumors received chemotherapy ± bevacizumab. Dual Factor VIII/Ki-67 immunohistochemical staining was performed on core needle biopsies at baseline and week 12. Microvessel density (MVD), proliferative microvessel density (pMVD; Factor VIII/Ki-67 co-expression), glomeruloid microvascular proliferation (GMP), and a gene expression angiogenesis signature score, were studied in relation to pathologic complete response (pCR), clinico-pathologic features and intrinsic molecular subtype. We found that high baseline MVD (by median) significantly predicted pCR in the bevacizumab-arm (odds ratio 4.9, P = 0.012). High pMVD, presence of GMP, and the angiogenesis signature score did not predict pCR, but were associated with basal-like (P ≤ 0.009) and triple negative phenotypes (P ≤ 0.041). pMVD and GMP did also associate with high-grade tumors (P ≤ 0.048). To conclude, high baseline MVD significantly predicted response to bevacizumab treatment. In contrast, pMVD, GMP, and the angiogenesis signature score, did not predict response, but associated with aggressive tumor features, including basal-like and triple-negative phenotypes.
format	article
author	Kristi Krüger Laxmi Silwal-Pandit Elisabeth Wik Oddbjørn Straume Ingunn M. Stefansson Elin Borgen Øystein Garred Bjørn Naume Olav Engebraaten Lars A. Akslen
author_facet	Kristi Krüger Laxmi Silwal-Pandit Elisabeth Wik Oddbjørn Straume Ingunn M. Stefansson Elin Borgen Øystein Garred Bjørn Naume Olav Engebraaten Lars A. Akslen
author_sort	Kristi Krüger
title	Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
title_short	Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
title_full	Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
title_fullStr	Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
title_full_unstemmed	Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
title_sort	baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/c8a2b3892eea4e2a921d64ce837fe2d4
work_keys_str_mv	AT kristikruger baselinemicrovesseldensitypredictsresponsetoneoadjuvantbevacizumabtreatmentoflocallyadvancedbreastcancer AT laxmisilwalpandit baselinemicrovesseldensitypredictsresponsetoneoadjuvantbevacizumabtreatmentoflocallyadvancedbreastcancer AT elisabethwik baselinemicrovesseldensitypredictsresponsetoneoadjuvantbevacizumabtreatmentoflocallyadvancedbreastcancer AT oddbjørnstraume baselinemicrovesseldensitypredictsresponsetoneoadjuvantbevacizumabtreatmentoflocallyadvancedbreastcancer AT ingunnmstefansson baselinemicrovesseldensitypredictsresponsetoneoadjuvantbevacizumabtreatmentoflocallyadvancedbreastcancer AT elinborgen baselinemicrovesseldensitypredictsresponsetoneoadjuvantbevacizumabtreatmentoflocallyadvancedbreastcancer AT øysteingarred baselinemicrovesseldensitypredictsresponsetoneoadjuvantbevacizumabtreatmentoflocallyadvancedbreastcancer AT bjørnnaume baselinemicrovesseldensitypredictsresponsetoneoadjuvantbevacizumabtreatmentoflocallyadvancedbreastcancer AT olavengebraaten baselinemicrovesseldensitypredictsresponsetoneoadjuvantbevacizumabtreatmentoflocallyadvancedbreastcancer AT larsaakslen baselinemicrovesseldensitypredictsresponsetoneoadjuvantbevacizumabtreatmentoflocallyadvancedbreastcancer
_version_	1718394599699906560

Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer

Ejemplares similares